Neural Therapeutics Inc. (CSE: NURL) ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use ...

Enveric receives its first patent for psychedelic-derived mescaline compounds. Non-hallucinogenic drugs aim to help with addiction, ADHD and anxiety. Feel unsure about the market’s next move?

Entitled “Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives,” the ‘439 patent is the first Enveric patent to be issued for its new EVM401 Series. Further development of the EVM401 ...

CAMBRIDGE, Mass., February 25, 2025--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the ...

Chennai: In what seems like a chemistry experiment gone wrong, the Narcotics Control Bureau (NCB) first declared that it had seized 28g of mescaline, a hallucinatory drug. Later, a forensic said ...

Mescaline, a natural hallucinogen known since ancient times, was not only a favorite of artists and bohemians but also a mainstay of brain research throughout the first half of the 20th century, until ...